The mucus produced in KRAS mutation lung adenocarcinoma and the rich blood supply of EGFR mutation lung adenocarcinoma may result in the lower quantitative value with KRAS mutations compared to EGFR mutations. This evidence concerns the gene EGFR and lung adenocarcinoma.